viewCytoDyn Inc.

CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus symptom study

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC).

Pourhassan says that after the first interim analysis, the DSMC requested a second one of all data after enrollment had reached 293 patients or 75% of the total patients for the trial. He says the group will continue to advance enrollment to achieve the trial’s planned 390 patients and are currently evaluating the ability to conduct an interim analysis as soon as possible.

Quick facts: CytoDyn Inc.

Price: 5.2 USD

Market: OTCQB
Market Cap: $3.11 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn files protocol with FDA for 'long-hauler' coronavirus patients in...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and Chief Medical Officer Scott Kelly tell Proactive the group filed a protocol with the FDA to conduct a Phase 2 clinical trial for leronlimab as a treatment for COVID-19 patients suffering from long-hauler symptoms. Kelly and Pourhassan...

on 11/17/2020

2 min read